2020 |
11/07 | 10:15 アルツハイマー病におけるアデュカヌマブに関するFDA諮問委員会について |
11/05 | 15:30 2020年度第2四半期決算説明会資料 |
11/05 | 12:30 2021年3月期第2四半期決算短信参考資料[IFRS] |
11/05 | 12:30 2021年3月期第2四半期決算短信[IFRS](連結) |
11/05 | 9,875 | 9,875 | 9,875 | 9,875 | +17.91% | 186,100 | 2兆9285億 | +10.99% |
11/04 | 8,330 | 8,442 | 8,194 | 8,375 | +2.38% | 782,500 | 2兆4837億 | -5.74% |
11/02 | 8,070 | 8,220 | 8,070 | 8,180 | +1.12% | 633,900 | 2兆4259億 | -8.46% |
10/30 | 20:00 アデュカヌマブ、アルツハイマー病治療薬として、欧州医薬品庁への販売承認申請が受理 |
10/30 | 8,307 | 8,379 | 8,076 | 8,089 | -3.3% | 1,124,300 | 2兆3989億 | -10.01% |
10/29 | 8,345 | 8,468 | 8,345 | 8,365 | -0.82% | 439,100 | 2兆4807億 | -7.5% |
10/28 | 8,440 | 8,488 | 8,393 | 8,434 | -0.28% | 488,000 | 2兆5012億 | -7.22% |
10/27 | 8,384 | 8,470 | 8,328 | 8,458 | +0.08% | 441,500 | 2兆5083億 | -7.42% |
10/26 | 8,439 | 8,494 | 8,390 | 8,451 | +1.45% | 449,100 | 2兆5062億 | -7.91% |
10/23 | 8,348 | 8,387 | 8,280 | 8,330 | -0.3% | 494,600 | 2兆4704億 | -9.61% |
10/22 | 8,559 | 8,559 | 8,342 | 8,355 | -2.51% | 521,400 | 2兆4778億 | -9.73% |
10/21 | 20:30 アデュカヌマブの欧州医薬品庁への販売承認申請の提出について |
10/21 | 8,590 | 8,603 | 8,518 | 8,570 | -0.79% | 452,500 | 2兆5415億 | -7.78% |
10/20 | 8,590 | 8,677 | 8,546 | 8,638 | -0.64% | 595,300 | 2兆5617億 | -7.33% |
10/19 | 8,590 | 8,698 | 8,566 | 8,694 | +1.66% | 687,400 | 2兆5783億 | -6.97% |
10/16 | 8,712 | 8,755 | 8,536 | 8,552 | -2.69% | 728,100 | 2兆5362億 | -8.69% |
10/15 | 8,875 | 8,904 | 8,731 | 8,788 | -1.71% | 727,400 | 2兆6062億 | -6.46% |
10/14 | 8,953 | 8,980 | 8,890 | 8,941 | -0.62% | 652,600 | 2兆6516億 | -5.07% |
10/13 | 9,267 | 9,282 | 8,953 | 8,997 | -3.29% | 1,013,500 | 2兆6682億 | -4.67% |
10/12 | 9,350 | 9,400 | 9,239 | 9,303 | -0.77% | 548,300 | 2兆7589億 | -1.66% |
10/09 | 9,591 | 9,592 | 9,328 | 9,375 | -2.49% | 1,029,400 | 2兆7803億 | -0.97% |
10/08 | 9,534 | 9,668 | 9,482 | 9,614 | +1.74% | 596,800 | 2兆8511億 | +1.52% |
10/07 | 9,633 | 9,680 | 9,416 | 9,450 | -3.2% | 790,300 | 2兆8025億 | -0.06% |
10/06 | 9,686 | 9,824 | 9,683 | 9,762 | +0.71% | 455,000 | 2兆8950億 | +3.38% |
10/05 | 9,645 | 9,780 | 9,600 | 9,693 | +1.57% | 658,400 | 2兆8746億 | +2.8% |
10/02 | 9,645 | 9,675 | 9,490 | 9,543 | -0.43% | 617,800 | 2兆8301億 | +1.33% |
09/30 | 9,625 | 9,691 | 9,551 | 9,584 | +0.13% | 929,300 | 2兆8422億 | +1.83% |
09/29 | 9,631 | 9,674 | 9,433 | 9,572 | -0.83% | 542,400 | 2兆8387億 | +1.79% |
09/28 | 9,599 | 9,660 | 9,518 | 9,652 | +1.37% | 692,900 | 2兆8624億 | +2.77% |
09/25 | 9,465 | 9,577 | 9,465 | 9,522 | +0.96% | 582,100 | 2兆8239億 | +1.5% |
09/24 | 9,523 | 9,540 | 9,383 | 9,431 | -1.23% | 552,600 | 2兆7969億 | +0.58% |
09/23 | 9,542 | 9,597 | 9,489 | 9,548 | -0.2% | 662,400 | 2兆8316億 | +1.83% |
09/18 | 9,500 | 9,582 | 9,441 | 9,567 | +0.78% | 777,400 | 2兆8372億 | +2% |
09/17 | 9,371 | 9,493 | 9,347 | 9,493 | +0.61% | 436,400 | 2兆8153億 | +1.17% |
09/16 | 9,317 | 9,447 | 9,295 | 9,435 | +1.17% | 511,700 | 2兆7981億 | +0.59% |
09/15 | 9,310 | 9,332 | 9,252 | 9,326 | +0.63% | 410,500 | 2兆7657億 | -0.51% |
09/14 | 9,242 | 9,295 | 9,229 | 9,268 | -0.13% | 399,700 | 2兆7485億 | -1.34% |
09/11 | 9,336 | 9,336 | 9,065 | 9,280 | +0.53% | 1,098,900 | 2兆7521億 | -0.94% |
09/10 | 9,294 | 9,317 | 9,181 | 9,231 | +0.2% | 588,800 | 2兆7376億 | -1.15% |
09/09 | 9,213 | 9,294 | 9,132 | 9,213 | -0.7% | 658,300 | 2兆7322億 | -1.1% |
09/08 | 9,375 | 9,458 | 9,200 | 9,278 | -1.35% | 713,900 | 2兆7515億 | -0.2% |
09/07 | 9,500 | 9,556 | 9,403 | 9,405 | -0.14% | 438,500 | 2兆7892億 | +1.38% |
09/04 | 9,399 | 9,487 | 9,381 | 9,418 | -1.37% | 537,000 | 2兆7930億 | +1.93% |
09/03 | 9,527 | 9,587 | 9,484 | 9,549 | +0.77% | 575,000 | 2兆8319億 | +3.62% |
09/02 | 9,365 | 9,500 | 9,340 | 9,476 | +0.42% | 546,200 | 2兆8102億 | +3.17% |
09/01 | 9,415 | 9,511 | 9,376 | 9,436 | +1.85% | 693,000 | 2兆7984億 | +3.05% |
08/31 | 9,290 | 9,342 | 9,181 | 9,265 | +1.37% | 723,600 | 2兆7476億 | +1.49% |
08/28 | 9,300 | 9,338 | 8,888 | 9,140 | -2.75% | 844,100 | 2兆7106億 | +0.34% |
08/27 | 9,401 | 9,416 | 9,350 | 9,398 | -0.12% | 296,900 | 2兆7871億 | +3.34% |
08/26 | 9,412 | 9,452 | 9,372 | 9,409 | -0.05% | 331,100 | 2兆7903億 | +3.85% |
08/25 | 9,440 | 9,503 | 9,365 | 9,414 | +0.41% | 555,300 | 2兆7918億 | +4.32% |
08/24 | 9,292 | 9,385 | 9,276 | 9,376 | +1.06% | 408,100 | 2兆7806億 | +4.4% |
08/21 | 9,364 | 9,396 | 9,266 | 9,278 | -0.87% | 712,000 | 2兆7515億 | +3.73% |
08/20 | 9,315 | 9,424 | 9,295 | 9,359 | -0.75% | 616,600 | 2兆7755億 | +4.95% |
08/19 | 9,370 | 9,485 | 9,356 | 9,430 | +0.14% | 792,100 | 2兆7966億 | +6.09% |
08/18 | 9,620 | 9,627 | 9,417 | 9,417 | -2.02% | 962,600 | 2兆7927億 | +6.27% |
08/17 | 9,610 | 9,638 | 9,559 | 9,611 | -0.62% | 629,300 | 2兆8503億 | +8.7% |
08/14 | 9,542 | 9,707 | 9,461 | 9,671 | +2.74% | 1,062,500 | 2兆8680億 | +9.91% |
08/13 | 9,498 | 9,528 | 9,310 | 9,413 | +1.3% | 1,021,100 | 2兆7915億 | +7.55% |
08/12 | 9,700 | 9,762 | 9,188 | 9,292 | -5.29% | 1,544,600 | 2兆7557億 | +6.56% |
08/11 | 9,226 | 9,890 | 9,223 | 9,811 | +13.74% | 2,951,200 | 2兆9096億 | +12.91% |
08/07 | 20:30 アデュカヌマブ、アルツハイマー病治療薬としてのBLA申請が米国FDAに受理され、優先審査に指定 |
08/07 | 8,688 | 8,690 | 8,537 | 8,626 | +1.03% | 578,400 | 2兆5581億 | -0.09% |
08/06 | 8,628 | 8,667 | 8,489 | 8,538 | -1.44% | 523,600 | 2兆5320億 | -1.07% |
08/05 | 8,760 | 8,760 | 8,550 | 8,663 | -1.01% | 568,200 | 2兆5691億 | +0.37% |
08/04 | 8,800 | 8,970 | 8,733 | 8,751 | -0.3% | 629,500 | 2兆5952億 | +1.45% |
08/03 | 15:30 2020年度第1四半期決算説明会資料 |
08/03 | 12:30 2021年3月期第1四半期決算短信参考資料〔IFRS〕 |
08/03 | 12:30 2021年3月期第1四半期決算短信〔IFRS〕(連結) |
08/03 | 8,637 | 8,839 | 8,505 | 8,777 | +3.42% | 889,300 | 2兆6029億 | +1.75% |
07/31 | 8,710 | 8,746 | 8,472 | 8,487 | -3.38% | 628,700 | 2兆5169億 | -1.54% |
07/30 | 8,750 | 8,812 | 8,680 | 8,784 | -0.13% | 359,200 | 2兆6050億 | +1.82% |
07/29 | 8,785 | 8,863 | 8,776 | 8,795 | +0.11% | 327,400 | 2兆6083億 | +2.03% |
07/28 | 8,840 | 8,871 | 8,753 | 8,785 | +0.45% | 443,900 | 2兆6053億 | +2.04% |
07/27 | 8,636 | 8,815 | 8,630 | 8,746 | +0.05% | 615,000 | 2兆5937億 | +1.73% |
07/22 | 8,667 | 8,775 | 8,640 | 8,742 | -0.29% | 462,900 | 2兆5925億 | +1.77% |
07/21 | 8,608 | 8,815 | 8,608 | 8,767 | +2.54% | 642,900 | 2兆6000億 | +2.14% |
07/20 | 8,475 | 8,572 | 8,454 | 8,550 | +0.48% | 372,100 | 2兆5356億 | -0.35% |
07/17 | 8,489 | 8,618 | 8,441 | 8,509 | +1.97% | 912,900 | 2兆5234億 | -0.64% |
07/16 | 8,447 | 8,504 | 8,312 | 8,345 | -1.37% | 947,300 | 2兆4748億 | -2.5% |
07/15 | 8,568 | 8,585 | 8,425 | 8,461 | -1.79% | 1,064,700 | 2兆5092億 | -1.21% |
07/14 | 8,625 | 8,723 | 8,575 | 8,615 | -0.28% | 484,700 | 2兆5549億 | +0.38% |
07/13 | 8,776 | 8,786 | 8,504 | 8,639 | -0.96% | 823,600 | 2兆5620億 | +0.56% |
07/10 | 8,948 | 8,972 | 8,719 | 8,723 | -2.51% | 1,134,700 | 2兆5869億 | +1.41% |
07/09 | 8,850 | 9,078 | 8,806 | 8,948 | +4.84% | 1,695,300 | 2兆6536億 | +4.01% |
07/08 | 20:30 アデュカヌマブ、アルツハイマー病治療薬として米国FDAへ生物製剤ライセンス申請完了 |
07/08 | 8,519 | 8,624 | 8,492 | 8,535 | +0.48% | 642,100 | 2兆5311億 | -0.64% |
07/07 | 8,581 | 8,581 | 8,451 | 8,494 | -1.4% | 456,700 | 2兆5190億 | -1.2% |
07/06 | 8,542 | 8,638 | 8,496 | 8,615 | +1.12% | 296,600 | 2兆5549億 | +0.17% |
07/03 | 8,500 | 8,539 | 8,429 | 8,520 | +1.13% | 380,800 | 2兆5267億 | -0.85% |
07/02 | 8,536 | 8,558 | 8,416 | 8,425 | -1.44% | 535,900 | 2兆4985億 | -1.92% |
07/01 | 8,689 | 8,735 | 8,520 | 8,548 | +0.02% | 596,500 | 2兆5350億 | -0.31% |
06/30 | 8,668 | 8,679 | 8,513 | 8,546 | +0.13% | 603,000 | 2兆5344億 | -0.05% |
06/29 | 17:00 投資単位の引下げに関する考え方および方針等について |
06/29 | 8,653 | 8,694 | 8,507 | 8,535 | -2.42% | 514,400 | 2兆5311億 | +0.22% |
06/26 | 8,722 | 8,771 | 8,650 | 8,747 | +1.34% | 523,100 | 2兆5940億 | +3.17% |
06/25 | 8,550 | 8,720 | 8,515 | 8,631 | -0.45% | 703,700 | 2兆5596億 | +2.37% |
06/24 | 8,625 | 8,765 | 8,564 | 8,670 | +0.76% | 597,200 | 2兆5712億 | +3.3% |
06/23 | 17:00 新株予約権証券の発行登録書の提出について |
06/23 | 8,553 | 8,658 | 8,361 | 8,605 | +1.01% | 667,200 | 2兆5519億 | +3.08% |
06/22 | 8,453 | 8,607 | 8,444 | 8,519 | +0.2% | 420,000 | 2兆5264億 | +2.6% |
06/19 | 17:00 当社企業価値・株主共同の利益の確保に関する対応方針(買収防衛策)の継続について |
06/19 | 8,598 | 8,598 | 8,436 | 8,502 | -0.7% | 951,300 | 2兆5214億 | +2.89% |
06/18 | 8,573 | 8,618 | 8,483 | 8,562 | +0.07% | 385,500 | 2兆5392億 | +4.15% |
06/17 | 8,665 | 8,665 | 8,530 | 8,556 | -1.63% | 637,200 | 2兆5374億 | +4.62% |
06/16 | 8,461 | 8,717 | 8,350 | 8,698 | +6.58% | 1,035,000 | 2兆5795億 | +6.95% |
06/15 | 8,330 | 8,462 | 8,150 | 8,161 | -2.51% | 548,100 | 2兆4202億 | +0.93% |
06/12 | 8,473 | 8,473 | 8,168 | 8,371 | -1.42% | 1,503,800 | 2兆4825億 | +3.9% |
06/11 | 8,660 | 8,710 | 8,482 | 8,492 | -4.54% | 1,199,900 | 2兆5184億 | +5.83% |
06/10 | 8,831 | 8,926 | 8,777 | 8,896 | +0.74% | 615,300 | 2兆6382億 | +11.46% |